Last 39 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.03 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 4.37 | 8.09 | 4.63 | 1.73 | 7.49 | 5.11 | 14.22 | 11.86 | 8.78 | 3.97 | — | — | — | 0.27 | 0.02 | 0.05 | 0.02 | 0.04 | 0.05 | 0.04 | 0.20 |
| — | +58.4% | -67.4% | -85.4% | -14.7% | +28.5% | — | — | — | +1391.3% | — | — | — | +503.9% | -52.8% | +11.5% | -88.3% | -51.1% | -3.0% | +32.1% | -76.5% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -169.2% | -44.2% | -34.2% | -35.9% | -39.2% | -65.0% | -54.5% | -73.6% | -204.7% | -61.9% | — | — | — | -84.5% | -47.4% | -42.6% | -42.9% | -42.1% | -35.4% | -40.1% | -50.4% |
| — | +31.9% | +37.3% | +51.2% | +80.8% | -5.1% | — | — | — | +26.8% | — | — | — | -100.9% | -33.9% | -6.2% | +14.9% | -6.8% | -24.8% | +78.6% | +73.7% | |
| ROA | -127.1% | -30.0% | -26.4% | -25.5% | -23.5% | -38.7% | -38.5% | -49.7% | -107.9% | -38.8% | -126.3% | -60.9% | -108.6% | -46.3% | -32.1% | -29.9% | -31.5% | -32.4% | -29.4% | -33.2% | -41.6% |
| — | +22.4% | +31.4% | +48.7% | +78.2% | +0.3% | +69.5% | +18.3% | +0.6% | +16.2% | -293.7% | -103.7% | -244.4% | -43.0% | -9.0% | +10.2% | +24.1% | +4.1% | -18.5% | +77.8% | +56.3% | |
| ROIC | -236.7% | -37.3% | -31.9% | -37.5% | -38.6% | -96.8% | -177.2% | -1049.0% | — | — | — | — | — | — | — | -123.3% | -273.5% | -15447.2% | — | — | -1060.8% |
| — | +61.5% | +82.0% | +96.4% | — | — | — | — | — | — | — | — | — | — | — | — | +74.2% | -2711.1% | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.02 | 0.01 | — | — | — | — | — | — | 0.02 | — | — | — | — | — | — |
| — | -23.4% | +18.0% | +141.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.78 | 0.18 | 1.15 | 0.78 | 0.40 | 0.83 | 3.00 | 3.68 | 0.64 | 2.45 | 1.09 | 0.63 | 0.23 | 1.06 | 3.09 | 2.83 | 2.32 | 3.32 | 4.36 | 6.70 | 4.24 |
| — | -78.4% | -61.6% | -78.8% | -38.2% | -66.2% | +173.8% | +480.1% | +173.3% | +130.6% | -64.6% | -77.6% | -89.9% | -68.1% | -29.2% | -57.7% | -45.3% | -49.3% | -32.9% | -30.3% | +311.5% | |
| Quick Ratio | 0.78 | 0.18 | 1.15 | 0.78 | 0.40 | 0.83 | 3.00 | 3.64 | 0.64 | 2.45 | 1.09 | 0.63 | 0.23 | 1.06 | 3.09 | 2.83 | 2.32 | 3.32 | 4.36 | 6.70 | 4.24 |
| — | -78.4% | -61.6% | -78.5% | -38.2% | -66.2% | +173.8% | +473.8% | +173.3% | +130.6% | -64.6% | -77.6% | -89.9% | -68.1% | -29.2% | -57.7% | -45.3% | -49.3% | -32.9% | -30.3% | +311.5% | |
| Interest Coverage | -47.06 | -18.72 | -268.41 | -10.11 | -428.62 | — | — | -10.47 | -1.79 | -1.71 | -17.98 | — | — | — | — | — | — | — | — | — | -248.33 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 39 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HURA stock.
TuHURA Biosciences, Inc.'s current P/E is -3.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking TuHURA Biosciences, Inc.'s business trajectory between earnings reports.